Treatment with investigational oral therapy BIIB122/DNL151 safely lowered the activity of disease biomarkers that reflect LRRK2 activity, a protein whose mutations are associated with Parkinson’s disease, according to results from two Phase 1 clinical studies. Plans are being put in place to advance the therapy into late-stage clinical testing…
News
D&D Pharmatech’s new subsidiary, Valted Seq, announced it has acquired exclusive rights from Johns Hopkins University to develop multiple biomarker assays for the evaluation and management of neurodegenerative diseases, including Parkinson’s. “There are currently no clinically accepted biomarker assays available for Parkinson’s disease. An assay capable of…
Parkinson’s disease experts worldwide, in a recent virtual meeting with the World Health Organization (WHO), discussed issues related to the neurodegenerative disease that will be the basis of a report to the United Nations detailing ways to improve life for patients and their families. The two-day meeting was reportedly the…
A rapid, inexpensive, and easy-to-use test can help to assess a loss of smell, and with greater accuracy than current “scratch and sniff” tests, allowing neurological disorders like Parkinson’s disease to be suspected at early stages, researchers report. Their study “A novel capsule-based smell test fabricated via coaxial…
The Michael J. Fox Foundation (MJFF) is hosting its second virtual walk event this weekend, and for the first time a three-day effort spanning May 7–9, to raise money to support research for Parkinson’s disease. Registration for the Virtual 5K/10K/Half Marathon is available online. Runners and walkers…
Disruptions in a network of interconnected nerves in the brain appear to underlie what are known as perception hallucinations in people with Parkinson’s disease, according to a recent study. This finding — taken from robotic-guided movements that act as a type of “brain stress test” — supports this network as a…
A review of current literature by Parkinson’s disease researchers worldwide found studies that attempted to classify the disease into a limited number of subtypes fall short in both methods and clinical applications. New approaches are needed in re-evaluating Parkinson’s disease subtypes, and should include those…
A new model of alpha-synuclein in Parkinson’s development, addressing both where aggregates first appear and their spread through the nervous system, may explain the variety of early symptoms, asymmetry in motor symptoms, and variability of disease progression seen in patients, a study reported. The study,…
Motor deficits, including problems with balance skills and gait or walking speed, are linked with non-motor symptoms of cognition — such as verbal fluency, memory, and attention — in people with Parkinson’s disease, a recent study suggests. Researchers believe these findings may help to identify cognitive deficits and…
Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read stories from the conference. Deep brain stimulation (DBS) can lessen motor function impairments and reduce the need for medication for up to 10 years in…
Recent Posts
- New compound targets mitochondrial damage in Parkinson’s models
- Environmental factors may impact Parkinson’s disease risk: Dutch study
- Finding solutions for REM sleep behavior disorder with Parkinson’s
- The benefits of pets for those of us with Parkinson’s disease
- Sometimes being a Parkinson’s caregiver means just standing by